Tumor microenvironment


A tumor is an ever-evolving and growing ecosystem of cells, an unhinged organ that takes root and spreads wherever it can. Though researchers have historically focused heavily on its constituent cancer cells, it has become abundantly clear in recent years that almost all tumors also depend on a supporting cast of noncancerous cells for their survival, metastasis and resistance to therapy. These include cells that ensure blood supply for nourishment and plumbing to ferry away waste, and those that make the fibrous infrastructure of tissues. They also include a variety of immune cells that help suppress tumor-targeting immune responses and aid the unbridled growth, drug resistance and migration of cancer cells. Several Ludwig researchers are deeply involved in analyzing how these various cells support malignant growth, with the aim of targeting such dependencies for cancer therapy.



Normalizing the tumor microenvironment to improve immunotherapy of cancer

Ludwig Harvard investigator Rakesh Jain discusses how the abnormal tumor vessels and matrix create a hostile microenvironment that fuels tumor progression and confers resistance to conventional and emerging cancer treatments.

You must enable Marketing cookies to watch this video.

Strategies to investigate and target the tumor microenvironment

Ludwig Lausanne’s Johanna Joyce introduces the general features of the tumor microenvironment; discusses critical functions of tumor-promoting myeloid cells in regulating cancer progression, metastasis and therapeutic resistance; and outlines current strategies for therapeutic targeting.

You must enable Marketing cookies to watch this video.

Convergence of the circadian clock and cancer

Ludwig Scientific Director Chi Van Dang has worked to unravel how the oncogene MYC links the aberrant metabolism of cancer cells to their unchecked proliferation.

You must enable Marketing cookies to watch this video.

Scale and complexity of hypoxia signaling pathways and their implications for cancer

Ludwig Oxford’s Peter Ratcliffe outlines the HIF hydroxylase pathway, discusses its evolution and considers its operation in health and disease.

You must enable Marketing cookies to watch this video.

Recent News


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?